Viridian Therapeutics (VRDN) News Today $23.82 -0.27 (-1.10%) As of 12:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Viridian Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Wednesday3 hours ago | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Has Average Target Price of $38.92October 25 at 6:43 AM | marketbeat.comViridian Therapeutics, Inc. $VRDN Shares Newly Acquired by AMI Asset Management CorpOctober 21, 2026 | marketbeat.comViridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026October 20, 2026 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Shares Up 7.8% - Here's WhyOctober 19, 2026 | marketbeat.comViridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales BaseOctober 17, 2026 | finance.yahoo.comRBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)October 10, 2026 | theglobeandmail.comViridian Therapeutics (NASDAQ:VRDN) Stock Dropped to Strong Sell by Wall Street ZenOctober 4, 2026 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% - Here's WhyOctober 1, 2026 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsSeptember 30, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)September 23, 2026 | theglobeandmail.comViridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC SaysSeptember 22, 2026 | finance.yahoo.comViridian Therapeutics: Two Products, One Commercial BuildoutSeptember 17, 2026 | seekingalpha.comViridian Intersects Over 50 Metres of Mineralization from Surface at Kraken MainSeptember 8, 2026 | globenewswire.comViridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare ConferenceSeptember 2, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)August 26, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)August 21, 2026 | theglobeandmail.comInsider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 SharesAugust 21, 2026 | insidertrades.comViridian Therapeutics Inc VRDNAugust 15, 2026 | morningstar.comMViridian Therapeutics (VRDN) Receives a Buy from LifeSci CapitalAugust 8, 2026 | theglobeandmail.comViridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets SaysAugust 8, 2026 | finance.yahoo.comViridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | businesswire.comViridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?July 15, 2026 | finance.yahoo.comViridian Therapeutics (VRDN) Stock Still Looks Above Fair Value TodayJuly 15, 2026 | finance.yahoo.comWedbush Sees Commercial Edge for Viridian (VRDN) After FDA MilestoneJuly 7, 2026 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - SlideshowJuly 1, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK)June 30, 2026 | theglobeandmail.comViridian Therapeutics: Lumvoa Ready For Prime Time Following FDA ApprovalJune 30, 2026 | seekingalpha.comViridian secures first FDA approval, sets up challenge to Amgen's Tepezza for thyroid eye diseaseJune 29, 2026 | msn.comViridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease TranscriptJune 29, 2026 | seekingalpha.comViridian launches first commercial product as U.S. approves thyroid eye disease therapyJune 27, 2026 | seekingalpha.comViridian launches first commercial product as US approves thyroid eye disease therapyJune 27, 2026 | msn.comVRDN stock jumps 6% after-hours as Viridian wins first FDA approvalJune 27, 2026 | msn.comViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye DiseaseJune 26, 2026 | businesswire.comViridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for InvestorsJune 25, 2026 | tipranks.comViridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market AppreciatesJune 25, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN)June 12, 2026 | theglobeandmail.comViridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comViridian Metals Commences 2026 Diamond Drill Program at the KrakenJune 9, 2026 | globenewswire.comViridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill ProgramJune 5, 2026 | globenewswire.comViridian Therapeutics Fully Repays Loan, Ends AgreementMay 28, 2026 | tipranks.comViridian Therapeutics secures WuXi deal for veligrotug manufacturingMay 26, 2026 | tipranks.comViridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350MMay 21, 2026 | finance.yahoo.comViridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel ProjectMay 19, 2026 | globenewswire.comViridian Therapeutics Announces Presentations at Multiple Medical Meetings in SeptemberMay 17, 2026 | businesswire.comThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMay 17, 2026 | fool.comViridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special MeetingMay 14, 2026 | globenewswire.comInsider Buying: Viridian Therapeutics (NASDAQ:VRDN) Director Acquires 1,176,470 Shares of StockMay 14, 2026 | insidertrades.comViridian Therapeutics Raises $359 Million in OfferingsMay 13, 2026 | theglobeandmail.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - SlideshowMay 9, 2026 | seekingalpha.com Viridian Therapeutics Media Mentions By Week Viridian Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼1.000.69▲Average Healthcare News Sentiment Viridian Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼34▲VRDN Articles Average Week Viridian Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views2,328-16% Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PTGX News Today TGTX News Today SYRE News Today ARWR News Today ABVX News Today CYTK News Today IONS News Today ALKS News Today PRAX News Today IOVA News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Viridian Therapeutics dated 10/28/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
